Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells
Compound 3, a thionated LVX derivative, showed a promising anticancer activity, prompting its potential repurposing for cancer treatment as well as combination treatment with DOX on DOX-resistant cancer cells.
Authors
- Osama H. Abusara (ORCID: https://orcid.org/0000-0002-0856-5618)
- Majed S. Al Yami (ORCID: https://orcid.org/0000-0003-2308-8407)
- Mohammad Abu‐Sini (ORCID: https://orcid.org/0000-0001-7352-9739)
- Hamza Abumansour (ORCID: https://orcid.org/0000-0003-3015-9859)
- Amal M. Badawoud (ORCID: https://orcid.org/0000-0001-7718-562X)
- Shiraz Halloush (ORCID: https://orcid.org/0000-0003-3966-2733)
- Dina H. Abulebdah (ORCID: https://orcid.org/0000-0002-8114-4334)
- Ali I. M. Ibrahim (ORCID: https://orcid.org/0000-0002-8668-4647)
- Wiam Khalil
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- University of Jordan (JO)
- Al-Zaytoonah University of Jordan (JO)
- Applied Science Private University (JO)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Abdulaziz Medical City (SA)
- King Abdullah International Medical Research Center (SA)
- National Guard Health Affairs (SA)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1371/journal.pone.0324930
- Citations
- 1
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Princess Nourah Bint Abdulrahman University
- Al-Zaytoonah University of Jordan